Abacavir oral sol.20mg/ml /BOT-240ml gb

General Description:
Abacavir oral solution 20mg/ml, bottle of 240ml with oral dispensing syringe

Technical Specifications:
Each 1 ml oral solution contains Abacavir Sulphate equivalent to 20mg Abacavir. Pack comes with oral dispensing syringe

Therapeutic class
Abacavir is a Nucleoside Reverse Transcriptase Inhibitor (NRTI)

Standard shelf life
24 Months

Other available formulations
The product may also be available in other formulations, pack sizes, or in combinations with other ARVs.

Guidelines for use
For more details, please see WHO treatment guidelines www.who.int/hiv/pub/guidelines/en/index.html and WHO Essential Medicines Library www.who.int/emlib/ or your regional/national guidelines.

Details about paediatric dosage schemes can be found at http://www.who.int/hiv/topics/paediatric/en/index.html

WHO generic tool for assessing paediatric ARV dosing
http://www.who.int/hiv/paediatric/generictool/en/

Indications
Management of HIV infection in children and adults in combination with at least one other antiretroviral drug. By mouth (oral) PO.
Can be taken without regard to food.
Management of HIV infection in combination with at least two other antiretroviral drugs.

Storage
Do not store above 30ºC
Store in a tightly closed container
Keep out of reach and sight of children

Once opened, oral solution must kept below 30ºC; may be stored for a maximum of 2 months

Dispensing instructions
Dispense in original container. Do not repack
Pack comes with Warning Card
Can be taken without regard to food

Note: Patients should be told the importance of regular dosing (intermittent therapy may increase sensitization), how to recognize signs of hypersensitivity, and advised to seek immediate medical attention if symptoms develop or before re-starting treatment.

Regulatory Status
For latest updates check the list of ‘Prequalified Medicines’ on the WHO website ‘Prequalification Programme’. apps.who.int/prequal/

For latest updates check the list of ‘USFDA approved and tentatively approved’ items on the USFDA website. www.fda.gov/default.htm, www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/